Neurexis Therapeutics develops therapeutic peptide for post-insult neuroprotection.
Neurexis Therapeutics has raised $3.0M in total funding. The most recent round was Grant. The last funding was announced in September 2024.
Neurexis Therapeutics's investors include VIC Technology Venture Development, National Institute of Neurological Disorders and Stroke, Colorado Office of Economic Development and International Trade.
Neurexis Therapeutics is headquartered in Aurora, United States.
Neurexis Therapeutics develops therapeutic peptide for post-insult neuroprotection.
Neurexis Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Neurexis Therapeutics — Funding & Investors." VCBacked, September 16, 2024, https://www.vcbacked.co/company/neurexis-therapeutics. Accessed August 14, 2026.
VCBacked. (2024). Neurexis Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/neurexis-therapeutics
{{cite web |title=Neurexis Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/neurexis-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated